Two Yale studies have identified a promising new antibody therapy and a previously unknown signaling pathway as potential treatments for fibrotic autoimmune diseases including scleroderma, lupus, and graft-versus-host disease.
The Colton Consortium sponsored the 2025 FASEB Autoimmunity Conference in Niagara Falls, a leading international forum dedicated to advancing autoimmune research and fostering collaboration among scientists and clinicians worldwide.
Penn Medicine has opened a new research facility housing the Colton Center for Autoimmunity alongside immune health, vaccinology, and infectious disease teams — designed to accelerate breakthrough science through collaboration.
Yale's Colton Center for Autoimmunity has selected nine researchers for nearly $1 million in 2025 funding, backing projects that apply AI, nanoparticles, and novel biologics to autoimmune disease.
Global leaders in autoimmune research gathered for the 2025 Colton Consortium Symposium last month, sharing breakthroughs from foundational science to translational therapies and forging collaborations to improve patient lives worldwide.
The Penn Colton Center has launched two new Centers of Excellence — HIT-AI, focused on AI-driven drug repurposing, and CREATE, pioneering mRNA therapies — to accelerate next-generation autoimmune diagnostics and treatments.
The Colton Center for Autoimmunity at Yale University presented a showcase on Colton-funded research featuring investigators from across the Consortium.
A Colton-supported NYU Langone study has engineered a bispecific antibody that precisely silences harmful T cell activity — showing promise across mouse models of type 1 diabetes, hepatitis, and multiple sclerosis.
The 2025 Penn Colton Center Symposium convened 150+ experts to explore breakthroughs in immune health and spotlight Penn's leadership, future headquarters, and innovations in autoimmunity research and precision medicine.
Yale researchers have found that a lupus-related antibody can penetrate "cold" tumors and activate immune responses — offering a promising new approach to treating glioblastoma and other hard-to-treat cancers.
